Technical Analysis for TRDA - Entrada Therapeutics, Inc.

Grade Last Price % Change Price Change
D 21.51 -3.37% -0.75
TRDA closed down 3.37 percent on Tuesday, December 7, 2021, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical TRDA trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -3.37%
Older End-of-Day Signals for TRDA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 10 hours ago
Fell Below Previous Day's Low about 13 hours ago
Down 2 % about 13 hours ago
Down 1% about 13 hours ago
Rose Above Lower Bollinger Band about 16 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Entrada Therapeutics, Inc. Description

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Diseases Medical Genetics Dystrophy Medical Terminology Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Genetic Genealogy Myotonic Dystrophy Neuromuscular Disease

Is TRDA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 36.85
52 Week Low 20.0
Average Volume 199,601
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 29.66
10-Day Moving Average 26.97
Average True Range 4.37
ADX 22.39
+DI 11.30
-DI 24.97
Chandelier Exit (Long, 3 ATRs) 23.74
Chandelier Exit (Short, 3 ATRs) 34.23
Upper Bollinger Bands 37.27
Lower Bollinger Band 22.05
Percent B (%b) -0.04
BandWidth 51.33
MACD Line -0.86
MACD Signal Line 0.13
MACD Histogram -0.985
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.78
Resistance 3 (R3) 26.12 25.05 25.07
Resistance 2 (R2) 25.05 23.96 24.87 24.83
Resistance 1 (R1) 23.28 23.29 22.74 22.93 24.59
Pivot Point 22.20 22.20 21.93 22.03 22.20
Support 1 (S1) 20.43 21.11 19.90 20.09 18.43
Support 2 (S2) 19.36 20.44 19.18 18.19
Support 3 (S3) 17.59 19.36 17.95
Support 4 (S4) 17.24